REGN currently has a PEG ratio reading of 43.83 as of Oct 2, 2026. This value reflects a P/E ratio of 17.53 measured against EPS growth of 0.4%. When compared to the trailing four-quarter average of 19.0, REGN's PEG ratio shows a 131% increase.
A ten years lookback shows an average PEG ratio of 6.24 for Regeneron Pharmaceuticals. Compared to historical data, REGN's 43.83 PE to growth ratio represents a rise of 602%. REGN reached its maximum PEG ratio of 86.9 during the Jun 2024 quarter over the past ten years. The Dec 2021 quarter had the bottom reading at 0.06, indicating the most optimal growth-adjusted valuation.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 3.38 | 17.92 | 5.3% |
| 2024 | 1.68 | 17.42 | 10.4% |
| 2023 | N/A | 23.71 | -8.5% |
| 2022 | N/A | 17.81 | -47% |
| 2021 | 0.06 | 8.27 | 134% |
| 2020 | 0.22 | 14.8 | 68.5% |
| 2019 | N/A | 19.37 | -14.4% |
| 2018 | 0.16 | 16.49 | 101% |
| 2017 | 1.05 | 33.36 | 31.8% |
| 2016 | 1.11 | 42.93 | 38.6% |
| 2015 | 1.05 | 87.99 | 83.6% |
| 2014 | N/A | 122.1 | -20.6% |
| 2013 | N/A | 65.07 | -46.6% |
| 2012 | 0.05 | 21.6 | 423.3% |
| 2011 | N/A | N/A | -94.4% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 37.18 | 14.87 | 0.4% |
| Mar 2026 | 9.55 | 18.15 | 1.9% |
| Dec 2025 | 3.38 | 17.92 | 5.3% |
| Sep 2025 | 25.88 | 12.94 | 0.5% |
| Jun 2025 | 3.49 | 12.57 | 3.6% |
| Mar 2025 | 0.97 | 15.18 | 15.6% |
| Dec 2024 | 1.68 | 17.42 | 10.4% |
| Sep 2024 | 1.55 | 24.31 | 15.7% |
| Jun 2024 | 86.9 | 26.07 | 0.3% |
| Mar 2024 | N/A | 26.65 | -7.5% |
| Dec 2023 | N/A | 23.71 | -8.5% |
| Sep 2023 | N/A | 22.02 | -25.7% |
| Jun 2023 | N/A | 17.87 | -24.7% |
| Mar 2023 | N/A | 21.04 | -47.9% |
| Dec 2022 | N/A | 17.81 | -47% |
Measured against past performance, REGN's PEG ratio is higher than its 3, 5 and 10-year averages.
With a PEG of 43.83, REGN is above the Healthcare sector and the industry average.
REGN has a PEG ratio above that of peer stocks AMGN and ALNY.
REGN's Oct 2, 2026 PEG ratio comes in at 43.83.
Over the last 3 years, REGN's PEG ratio has settled near 18.95.
Over the last 5 years, REGN's PEG ratio has settled near 15.52.
In the last ten years, REGN's peak PEG ratio of 86.9 was recorded in the Jun 2024 quarter.
Currently, REGN's PEG ratio stands 602% higher than its 10-year historical average.
Slow earnings growth combined with a high valuation pushes REGN's PEG ratio to 43.83.
Computing the PEG ratio involves dividing the PE ratio by the company's EPS growth (YoY TTM). As of Oct 2, 2026, Regeneron Pharmaceuticals has a P/E ratio of 17.53. Earnings grew at 0.4% over the TTM period ending Jun 2026. Applying the formula, this produces a price to earnings growth ratio of 43.83. PEG RATIO(43.83) = PE RATIO(17.53) / EPS GROWTH(0.4%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.